Skip Navigation

European Heart Journal 1993 14(Supplement B):40-47; doi:10.1093/eurheartj/14.suppl_B.40
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kato, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

Haemodynamic and clinical effects of an intravenous potassium channel opener — a review

K. Kato

The Cardiovascular Institute 3-10 Roppongi 7-chome Minato-ku, 106 Tokyo, Japan

Correspondence: K. Kato, MD, The Cardiovascular Institute, 3-10 Roppongi 7-chome Minato-Ku, 106 Tokyo, Japan.

Intravenous nicorandil (4–12 mg) produced a significant decrease in mean arterial blood pressure (– 5 to –15%), systemic vascular resistance (–8 to –27%), pulmonary capillary wedge pressure (–15 to –41%) and left ventricular end-diastolic pressure (–8 to –18%) in patients with coronary artery disease, myocardial infarction or congestive heart failure. Cardiac output was significantly increased (+3 to +19%) in most studies. These haemodynamic effects of intravenous nicorandil (4–8 mg) were comparable to those of nitroglycerin (0.3 mg), although a greater decrease in preload was produced by nitroglycerin. Moreover, no significant haemodynamic tolerance developed over a 12 to 24 h period during continuous infusion of nicorandil (2.4 µg . kg– . min–) in patients with heart failure, in contrast to nitroglycerin infusion (0-65 µg . kg–1 . min–1). Intravenous nicorandil (4–12 mg) was also shown to produce a slightly smaller increase (8–27±) in the diameter of the large coronary arteries compared to that of sublingual nitroglycerin (0.3 mg) (16–32%) and to cause a significant decrease in coronary vascular resistance (–9 to –53%) and a significant increase in coronary sinus flow (+6 to +81–) in patients with coronary artery disease. The efficacy of intravenous nicorandil (2–6 mg . h–1) in unstable angina pectoris has been compared with that of isosorbide dinitrate (2–5 mg . h–1) in a doubleblind, multicentre trial. Over a 3 to 9 day period, nicorandil therapy tended to be more effective in abolishing anginal attacks and decreasing nitroglycerin consumption.

Key Words: Intravenous nicorandil • nitroglycerin • isosorbide dinitrate • tolerance • unstable angina


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.